Asset profile
INV-101
Small molecule
Evidence outlook · lead readout
NCT05844592 · Ulcerative Colitis
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05844592: This trial randomized 40 healthy volunteers to ascending doses of INV-101 or placebo under double-blind conditions, but it measured only safety (adverse events), not efficacy, and results have not yet been reported.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.